Data-Rich Year Ahead - Will 2026 Readouts Lift Climb Bio Higher

For Climb Bio Inc. (CLYM), 2026 promises to be a data-rich year, with study results from two of its core programs poised to shape the company's strategy and guide subsequent development phases.The company is focused on delivering disease-modifying medicines for individuals living with immune-mediated diseases. Its drug candidates in focus are Budoprutug and CLYM116.Budoprutug is an anti-CD19 monoclonal antibody (mAb) designed to result in potent and durable B cell depletion, with a long dosing interval and ...